New Delhi India’s drug regulator on Friday approved the Serum Institute of India’s proposal to make a drug substance for the new COVID vaccine against the Omicron type of coronavirus and test and analyze it, official sources said.
The move assumes significance in the wake of the country reporting an increase in new COVID-19 cases daily, including the Omron version.
In order to conduct vaccine research against the Omicron variant, Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII, recently gave a nod to the Drug Controller General of India (DCGI) to allow the manufacturing of a drug substance for SARS-CoV. Application was submitted. Recombinant spike nanoparticle vaccine (Omicron variant) for 2RS protein (COVID-l9) test test and analysis.
“As you know, the new coronavirus variant ‘Omicron’ has already been reported in more than 60 countries and it is spreading very fast around the world and also in our country. Our CEO Adar C Poonawalla is our citizens An official source quoted Singh as saying, “The country and the world at large against the coronavirus and its new forms, and we are facing the SARS-CoV-2 rS protein (COVID-19) recombinant spike.” Continuously working on the development of nanoparticle vaccine (Omicron variant) in application.
He said that the development of this vaccine would be another example of India’s vaccine production prowess in line with Prime Minister Narendra Modi’s call of “Making in India for the world” and would keep our country’s flag high on the world stage.
After reviewing their application, DCGI has given permission for the manufacture of SARS-CoV-2 rS drug substance.omicron variant) for examination, testing and analysis (for the SIIPL Hadapsar site), an official source said.
,